XBP1 and acute myeloid leukemia: The potential of IRE1α inhibition, a component of the UPR, by agents such as MKC-3946, 2-hydroxy-1-naphthaldehyde (HNA), STF-083010, and toyocamycin, to disrupt XBP1 mRNA splicing and show cytotoxic effects against AML cells is a promising research area [96,97,98,99,100].